| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10917835 | Radiotherapy and Oncology | 2016 | 6 Pages |
Abstract
High tumor glycine concentration was identified as adverse prognostic factor for PFS in LARC. In a patient population treated with curative intent but with metastatic disease as main PFS event further investigations of glycine as early predictor of metastatic progression and therapeutic target are warranted.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Kathrine Røe Redalen, Beathe Sitter, Tone Frost Bathen, Krystyna K. Grøholt, Knut Håkon Hole, Svein Dueland, Kjersti Flatmark, Anne Hansen Ree, Therese Seierstad,